Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2

Behavioural Pharmacology

Volumn 15, Issue 1, 2004, Pages 45-54

  Bertoglio, L J ^a   Carobrez, A P ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anxiety; Elevated plus maze; Memantine; Midazolam; One trial tolerance; Rat; Scopolamine

Indexed keywords

MEMANTINE; MIDAZOLAM; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; EXPLORATORY BEHAVIOR; EXPOSURE; LEARNING; MALE; MAZE TEST; NONHUMAN; RAT; TIME; TRANQUILIZING ACTIVITY;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANTI-ANXIETY AGENTS; AROUSAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEAR; MALE; MAZE LEARNING; MEMANTINE; MEMORY, SHORT-TERM; MIDAZOLAM; PREMEDICATION; RATS; RATS, WISTAR; SCOPOLAMINE;

EID: 1242317111     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200402000-00006     Document Type: Article

References (47)

1. Aigner TG, Walker DL, Mishkin M (1991). Comparison of the effects of scopolamine administered before and after acquisition in a test of visual recognition memory in monkeys. Behav Neural Biol 55:61-67.
2. Andersen JM, Lindberg V, Myhrer T (2002). Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav Brain Res 129:211-216.
3. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C (1985). The cholinergic hypothesis: a historical overview, current perspective and future directions. In: Olton DS, Gamzu E, Corkin S (editors): Memory Dysfunctions: An Integration of Animal and Human Research from Preclinical and Clinical Perspectives. New York: NY Acad Sci; pp. 408-417.
4. Bertoglio LJ, Carobrez AP (2000). Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav Brain Res 108:197-203.
5. Bertoglio LJ, Carobrez AP (2002a). Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze. Pharmacol Biochem Behav 73:963-969.
6. Bertoglio LJ, Carobrez AP (2002b). Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav Brain Res 132:135-143.
7. Bertoglio LJ, Carobrez AP (2002c). Prior maze experience required to alter midazolam effects in rats submitted to the elevated plus-maze. Pharmacol Biochem Behav 72:449-455.
8. Bertoglio LJ, Carobrez AP (2003). Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze Trial 2 in rats. Psychopharmacology 170:335-342.
9. Blokland A (1996). Acetylcnoline: a neurotransmitter for learning and memory? Brain Res Rev 21:285-300.
10. Bolhuis JJ, Strijkstra AM, Kramers RJ (1988). Effects of scopolamine on performance of rats in a delayed-response radial maze task. Physiol Behav 43:403-409.
11. Canto-de-Souza A, Nunes-de-Souza RL, Rodgers RJ (2002). Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res 928:50-59.
12. Cruz-Morales SE, Santos NR, Brandão ML (2002). One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic- sensitive behaviors in the elevated plus-maze retest in the rat. Pharmacol Biochem Behav 72:973-978.
13. Dal-Cól MLC, Orlandi-Pereira L, Rosa VP, Calixto AV, Carobrez AP, Faria MS (2003). Lack of midazolam-induced anxiolysis in the plus-maze Trial 2 is dependent on the length of Trial 1. Pharmacol Biochem Behav 74:395-400.
14. Dawson GR, Crawford SP, Stanhope KJ, Iversen SD, Tricklebank MD (1994). One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology 113:570-572.
15. De-Mello N, Carobrez AP (2002). Elevated T-maze as an animal model of memory: effects of scopolamine. Behav Pharmacol 13:139-148.
16. Deutsch JA (1971). The cholinergic synapse and the site of memory. Science 174:788-794.
17. Dunne MP, Hartley LR (1986). Scopolamine and the control of attention in humans. Psychopharmacology 89:94-97.
18. Fernandes C, File SE (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 49:21-30.
19. File SE (1993). The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res 58:199-202.
20. File SE, Zangrossi H Jr (1993). 'One-trial tolerance' to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology 110:240-244.
21. File SE, Mabbutt PS, Hitchcott PK (1990). Characterisation of the phenomenon of 'one-trial tolerance' to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102:98-101.
22. File SE, Zangrossi H Jr, Viana M, Graeff FG (1993). Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology 111:491-494.
23. Frussa-Filho R, Ribeiro R de A (2002). One-trial tolerance to the effects of chlordiazepoxide in the elevated plus-maze is not due to acquisition of a phobic avoidance of open arms during initial exposure. Life Sci 71:519-525.
24. Gonzalez LE, File SE (1997). A five-minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neurosci 17:1505-1511.
25. Gray AJ, McNaughton N (2000). The Neuropsychology of Anxiety. 2nd ed. New York: Oxford University Press; pp. 72-82.
26. Handley SL, McBlane JW (1993). An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Math 29:129-138.
27. Hascoet M, Bourin M, Couetoux du Tertre A (1997). Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav 58:1131-1138.
28. Holmes A, Rodgers RJ (1998). Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav 60:473-488.
29. Holmes A, Iles JP, Mayell SJ, Rodgers RJ (2001). Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav Brain Res 122:159-167.
30. Itoh J, Nabeshima T, Kameyama T (1991). Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 194:71-76.
31. Jones DN, Higgins GA (1995). Effect of scopolamine on visual attention in rats. Psychopharmacology 120:142-149.
32. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185.
33. Martinez JC, Cardenas F, Lamprea M, Morato S (2002). The role of vision and proprioception in the aversion of rats to the open arms of an elevated plus-maze. Behav Process 60:15-26.
34. McGregor IS, Dielenberg RA (1999). Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats. Psychopharmacology 147:174-181.
35. McNaughton N, Morris RG (1987). Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. Behav Brain Res 24:39-46.
36. Mintzer MZ, Griffiths RR (2003). Lorazepam and scopolamine: a single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol 11:56-72.
37. Miyazaki S, Imaizumi M, Onodera K (1995). Ameliorating effects of histidine on learning deficits in an elevated plus-maze test in mice and the contribution of cholinergic neuronal systems. Methods Find Exp Clin Pharmacol 17:57-63.
38. Myhrer T (2003). Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Rev 41: 268-287.
39. Nunes-de-Souza RL, Canto-de-Souza A, Rodgers RJ (2002). Effects of intrahippocampal infusion of WAY-100635 on plus-maze behavior in mice. Influence of site of injection and prior test experience. Brain Res 927:87-96.
40. Parsons MW, Gold PE (1992). Scopolamine-induced deficits in spontaneous alternation performance: attenuation with lateral ventricle injections of glucose. Behav Neural Biol 57:90-92.
41. Rodgers RJ, Shepherd JK (1993). Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113:237-242.
42. Rogers RJ, Lee C, Shepherd JK (1992). Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106:102-110.
43. Rodgers RJ, Johnson NJT, Cole JC, Dewar CV, Kidd GR, Kimpson PH (1996). Plus-maze retest profile in mice: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade. Pharmacol Biochem Behav 54:41-50.
44. Saucier D, Hargreaves EL, Boon F, Vanderwolf CH, Cain DP (1996). Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Behav Neurosci 110:103-116.
45. Soffie M, Lamberty Y (1987). Scopolamine disrupts visual reversal without affecting the first discrimination. Physiol Behav 40:263-265.
46. Treit D, Menard J, Royan C (1993). Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463-469.
47. Zanotti A, Valzelli L, Toffano G (1986). Reversal of scopolamine-induced amnesia by phosphatidylserine in rats. Psychopharmacology 90:274-275.